PE20211307A1 - ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS - Google Patents
ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADASInfo
- Publication number
- PE20211307A1 PE20211307A1 PE2020001854A PE2020001854A PE20211307A1 PE 20211307 A1 PE20211307 A1 PE 20211307A1 PE 2020001854 A PE2020001854 A PE 2020001854A PE 2020001854 A PE2020001854 A PE 2020001854A PE 20211307 A1 PE20211307 A1 PE 20211307A1
- Authority
- PE
- Peru
- Prior art keywords
- rur20kd
- related compositions
- compositions
- selective treg
- treg stimulator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invencion se refiere a composiciones de estimulador de Treg selectivo, que incluyen conjugados de IL-2 PEGilados que tiene la estructura ( ), en donde la porcion IL-2 es interleucina-2, n es un numero entero de 3 a 4000. Tambien se refiere a composiciones relacionadas y metodos de uso de estas composiciones, por ejemplo, para tratar enfermedades autoinmunitarias y/u otras afecciones que responden al tratamiento que es eficaz para proporcionar un aumento de las cantidades y la activacion de los linfocitos T reguladores sobre los linfocitos T efectores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862674244P | 2018-05-21 | 2018-05-21 | |
PCT/US2019/033100 WO2019226538A1 (en) | 2018-05-21 | 2019-05-20 | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211307A1 true PE20211307A1 (es) | 2021-07-20 |
Family
ID=67002369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020001854A PE20211307A1 (es) | 2018-05-21 | 2019-05-20 | ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS |
Country Status (19)
Country | Link |
---|---|
US (1) | US20210205413A1 (es) |
EP (1) | EP3796940A1 (es) |
JP (2) | JP7235772B2 (es) |
KR (1) | KR20210002577A (es) |
CN (1) | CN112399859A (es) |
AU (2) | AU2019274409B2 (es) |
BR (1) | BR112020021564A2 (es) |
CA (1) | CA3100204A1 (es) |
CL (1) | CL2020003008A1 (es) |
CO (1) | CO2020014510A2 (es) |
CR (1) | CR20200546A (es) |
DO (1) | DOP2020000212A (es) |
EA (1) | EA202092489A1 (es) |
EC (1) | ECSP20074392A (es) |
JO (1) | JOP20200290A1 (es) |
PE (1) | PE20211307A1 (es) |
PH (1) | PH12020551976A1 (es) |
SG (1) | SG11202011242SA (es) |
WO (1) | WO2019226538A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021206449A1 (en) | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
EP4092048A4 (en) * | 2020-01-15 | 2023-07-26 | Jenkem Technology Co. Ltd. (Tianjin) | METHOD FOR PREPARING PEGYLATED BIOMOLECULES HAVING CONTROLLABLE BINDING SITES |
CN113121670B (zh) * | 2020-01-15 | 2022-11-22 | 天津键凯科技有限公司 | 二取代peg化白细胞介素2及其制备方法、应用 |
WO2021236474A1 (en) * | 2020-05-22 | 2021-11-25 | Merck Sharp & Dohme Corp. | Novel processes for preparing conjugates of the il-2 protein |
TW202228784A (zh) | 2020-09-23 | 2022-08-01 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗peg抗體的化合物 |
US20230414720A1 (en) * | 2020-11-23 | 2023-12-28 | University Of Florida Research Foundation, Incorporated | Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes |
WO2023114833A1 (en) | 2021-12-14 | 2023-06-22 | Eli Lilly And Company | Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4401756A (en) | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5153310A (en) | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
FR2826365B1 (fr) | 2001-06-20 | 2003-09-26 | Oreal | Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile |
JP5048332B2 (ja) | 2003-05-23 | 2012-10-17 | ネクター セラピューティクス | 特定の原子配置を有するポリマー誘導体 |
US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
US7567215B1 (en) | 2007-10-23 | 2009-07-28 | The United States Of America As Represented By The Secretary Of The Navy | Portable and inflatable antenna device |
KR102472497B1 (ko) * | 2010-11-12 | 2022-11-29 | 넥타르 테라퓨틱스 | Il-2 부분 및 중합체의 접합체 |
PL2683395T3 (pl) * | 2011-03-11 | 2019-04-30 | Assist Publique Hopitaux De Paris | Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1 |
US10898576B2 (en) * | 2016-03-16 | 2021-01-26 | Yanhui Xie | Glucocorticoid combined with polyethylene glycol-modified interleukin 2 for treating respiratory disease |
-
2019
- 2019-05-20 CA CA3100204A patent/CA3100204A1/en active Pending
- 2019-05-20 CR CR20200546A patent/CR20200546A/es unknown
- 2019-05-20 KR KR1020207033346A patent/KR20210002577A/ko not_active Application Discontinuation
- 2019-05-20 EP EP19732788.5A patent/EP3796940A1/en active Pending
- 2019-05-20 PE PE2020001854A patent/PE20211307A1/es unknown
- 2019-05-20 JO JOP/2020/0290A patent/JOP20200290A1/ar unknown
- 2019-05-20 AU AU2019274409A patent/AU2019274409B2/en active Active
- 2019-05-20 CN CN201980034052.1A patent/CN112399859A/zh active Pending
- 2019-05-20 JP JP2020564540A patent/JP7235772B2/ja active Active
- 2019-05-20 SG SG11202011242SA patent/SG11202011242SA/en unknown
- 2019-05-20 BR BR112020021564-3A patent/BR112020021564A2/pt unknown
- 2019-05-20 US US17/056,050 patent/US20210205413A1/en active Pending
- 2019-05-20 EA EA202092489A patent/EA202092489A1/ru unknown
- 2019-05-20 WO PCT/US2019/033100 patent/WO2019226538A1/en active Application Filing
-
2020
- 2020-11-18 PH PH12020551976A patent/PH12020551976A1/en unknown
- 2020-11-19 CL CL2020003008A patent/CL2020003008A1/es unknown
- 2020-11-19 DO DO2020000212A patent/DOP2020000212A/es unknown
- 2020-11-20 EC ECSENADI202074392A patent/ECSP20074392A/es unknown
- 2020-11-23 CO CONC2020/0014510A patent/CO2020014510A2/es unknown
-
2022
- 2022-10-06 AU AU2022246440A patent/AU2022246440A1/en active Pending
- 2022-12-23 JP JP2022206250A patent/JP2023052053A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN112399859A (zh) | 2021-02-23 |
ECSP20074392A (es) | 2021-03-31 |
KR20210002577A (ko) | 2021-01-08 |
AU2019274409B2 (en) | 2022-07-14 |
BR112020021564A2 (pt) | 2021-03-02 |
JOP20200290A1 (ar) | 2020-11-15 |
DOP2020000212A (es) | 2021-03-15 |
WO2019226538A1 (en) | 2019-11-28 |
JP2023052053A (ja) | 2023-04-11 |
CO2020014510A2 (es) | 2021-03-08 |
JP2021523922A (ja) | 2021-09-09 |
EA202092489A1 (ru) | 2021-03-16 |
CL2020003008A1 (es) | 2021-07-30 |
CR20200546A (es) | 2021-05-18 |
US20210205413A1 (en) | 2021-07-08 |
JP7235772B2 (ja) | 2023-03-08 |
EP3796940A1 (en) | 2021-03-31 |
PH12020551976A1 (en) | 2021-09-13 |
AU2019274409A1 (en) | 2020-11-12 |
CA3100204A1 (en) | 2019-11-28 |
AU2022246440A1 (en) | 2022-11-03 |
SG11202011242SA (en) | 2020-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211307A1 (es) | ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS | |
CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
CL2018001845A1 (es) | Moduladores de la 5'-nucleotidasa, ecto y su uso | |
CL2019003233A1 (es) | Virus de la enfermedad de newcastle y usos de los mismos. | |
CL2020002161A1 (es) | Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano. | |
CO4290424A1 (es) | Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina | |
CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
ES2131589T3 (es) | Sulfonamidas inhibidoras de aspartil-proteasa del vih. | |
BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
CL2022002247A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 (divisional de la solicitud 202001703) | |
BR112021016056A2 (pt) | Anticorpos de claudina 6 e usos dos mesmos | |
MX2022002740A (es) | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. | |
BR112021016613A2 (pt) | Agente capaz de inibir a sinalização mediada por interleucina 11 (il-11), uso deste na fabricação de um medicamento e métodos | |
ECSP21052193A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
CO2021010786A2 (es) | Toxinas apxia, apxiia y apxiiia inactivadas | |
CO2021014260A2 (es) | Formas sólidas de un inhibidor de glyt1 | |
CR20230100A (es) | Compuestos fosfolípidos y usos de los mismos | |
CO2021013171A2 (es) | Compuestos y composiciones como moduladores de la señalización de tlr | |
CO2023005057A2 (es) | Compuestos y composiciones como moduladores de señalización tlr | |
BR112017016110A2 (pt) | composições de imunoglobulina equina e usos para tratamento de doenças mediadas por filovírus | |
ES2043901T3 (es) | Adyuvante para la terapia inmunologica del cancer. | |
CO2021014748A2 (es) | Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo | |
BR112023002926A2 (pt) | Agentes terapêuticos inaláveis | |
CO2021002980A2 (es) | Formulaciones de dendrímeros |